Sometimes a great notion - An assessment of neoadjuvant systemic therapy for breast cancer

Journal of the National Cancer Institute

Volumn 97, Issue 3, 2005, Pages 159-161

  Davidson, Nancy E ^a   Morrow, Monica ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ANTINEOPLASTIC AGENT;

BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE MODEL; EDITORIAL; EXPECTATION; FOLLOW UP; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HISTOPATHOLOGY; HUMAN; INDIVIDUALIZATION; MAMMOGRAPHY; MEDICAL ASSESSMENT; MEDICAL DECISION MAKING; MEDICAL LITERATURE; MEDICAL SPECIALIST; META ANALYSIS; METHODOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTIAL MASTECTOMY; PATIENT CARE; PEER REVIEW; PHYSICAL EXAMINATION; PREDICTION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RAT; RECURRENCE RISK; RELIABILITY; SYSTEMATIC REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BREAST TUMOR; FEMALE; PATHOLOGY; RISK ASSESSMENT; SEGMENTAL MASTECTOMY; STATISTICS; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MASTECTOMY, SEGMENTAL; META-ANALYSIS; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RISK ASSESSMENT;

EID: 13744254004     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/dji049     Document Type: Editorial

References (14)

1. Wolff AC, Davidson NE. Primary systemic therapy in operable breast cancer. J Clin Oncol 2000;18:1558-69.
2. Kaufmann M, von Minckwitz G, Smith R, Valero V, Gianni L, Eiermann W, et al. International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol 2003;21:2600-8.
3. Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment for breast cancer: a meta-analysis. J Natl Cancer Inst 2005;97: 188-94.
4. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001;30:96-102.
5. van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 2001;19:4224-37.
6. Makris A, Powles TJ, Ashley SE, Chang J, Hickish T, Tidy VA, et al. A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol 1998;9:1179-84.
7. Helvie MA, Joynt LK, Cody RL, Pierce LJ, Adler DD, Merajver SD. Locally advanced breast carcinoma: accuracy of mammography versus clinical examination in the prediction of residual disease after chemotherapy. Radiology 1996;198:327-32.
8. Rosen EL, Blackwell KL, Baker JA, Soo MS, Bentley RC, Yu D, et al. Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy. AJR Am J Roentgenol 2003;181:1275-82.
9. Martincich L, Montemurro F, DeRosa G, Marra V, Ponzone R, Cirillo S, et al. Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging. Breast Cancer Res Treat 2004;83:67-76.
10. Fisher B, Bryant J, Wolmark N, Mamounas E Brown A, Fisher ER, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16:2672-85.
11. Bear H, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003;21:4165-74.
12. Bear HD, Anderson S, Smith RE, Robidoux A, Kahlenberg MS, Margolese RG, et al. A randomized trial comparing preoperative (preop) doxorubicin/cyclophosphamide (AC) to preop, AC followed by preop docetaxel (T) and to preop AC followed by postoperative (postop) T in patients (pts) with operable carcinoma of the breast: results of NSABP B-27. Breast Cancer Res Treat 2004;88(Suppl1):S16 (abstract 26).
13. Fisher ER, Wang J, Bryant J, Fisher B, Mamounas E, Wolmark N. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer 2002;95: 681-95.
14. Wang J, Buchholz TA, Middleton LP, Allred DC, Tucker SL, Kuerer H, et al. Assessment of histologic features and expression of biomarkers in predicting pathologic response to anthracycline-based neoadjuvant chemotherapy in patients with breast carcinoma. Cancer 2002;94:3107-14.